Clinical Trials
158
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1991
Completed
119
75.3%
Not yet recruiting
2
1.3%
Recruiting
19
12.0%
Unknown
17
10.8%
Withdrawn
1
0.6%
No approval data available
- Researchers developed namiRa by systematically curating 9,983 scientific publications, integrating experimentally validated data on 1,095 human miRNAs across 33 cancer types. - The database provides multi-layered evidence including miRNA expression patterns, functional characterization from in vitro and in vivo studies, validated target genes, and interactive regulatory network visualization. - namiRa aims to accelerate cancer biomarker discovery, therapeutic target identification, and data-driven precision medicine research. - The study was published in Computers in Biology and Medicine (Elsevier) and the database is freely accessible at www.namira-db.com.
- Iran has approved WhartoCell, an allogeneic mesenchymal stem cell therapy derived from Wharton's jelly of neonatal umbilical cord, for treating osteoarthritis. - The therapy is designed to reduce inflammation, support cartilage regeneration, and improve joint function without requiring HLA matching between donor and recipient. - Developed by Royan Institute under GMP standards, WhartoCell is positioned as an off-the-shelf treatment to improve patient access to regenerative medicine. - Researchers indicate potential broader applications including cartilage repair, tendon and ligament injuries, bone fracture healing, and avascular necrosis.
